NIHR Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, Imperial College, London, UK.
R&D, GlaxoSmithKline King of Prussia, Philadelphia, Pennsylvania, USA.
Thorax. 2018 Dec;73(12):1182-1185. doi: 10.1136/thoraxjnl-2018-211556. Epub 2018 Apr 4.
Cardiovascular and skeletal muscle manifestations constitute important comorbidities in COPD, with systemic inflammation proposed as a common mechanistic link. Fibrinogen has prognostic role in COPD. We aimed to determine whether aortic stiffness and quadriceps weakness are linked in COPD, and whether they are associated with the systemic inflammatory mediator-fibrinogen. Aortic pulse wave velocity (aPWV), quadriceps maximal volitional contraction (QMVC) force and fibrinogen were measured in 729 patients with stable, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II-IV COPD. The cardiovascular and muscular manifestations exist independently (P=0.22, χ). Fibrinogen was not associated with aPWV or QMVC (P=0.628 and P=0.621, respectively), making inflammation, as measured by plasma fibrinogen, an unlikely common aetiological factor.
心血管和骨骼肌肉表现是 COPD 的重要合并症，全身炎症被认为是一种共同的发病机制。纤维蛋白原在 COPD 中有预后作用。我们旨在确定 COPD 中主动脉僵硬和股四头肌无力是否相关，以及它们是否与全身炎症介质-纤维蛋白原相关。在 729 名稳定的、全球慢性阻塞性肺疾病倡议（GOLD）II-IV 期 COPD 患者中测量了主动脉脉搏波速度（aPWV）、股四头肌最大随意收缩（QMVC）力和纤维蛋白原。心血管和肌肉表现是独立存在的（P=0.22，χ）。纤维蛋白原与 aPWV 或 QMVC 无关（P=0.628 和 P=0.621），这表明血浆纤维蛋白原所测量的炎症不太可能是共同的病因。
